Craig Chaya is an Ophthalmology physician affiliated with University of Utah. OpenAlex indexes 29 publications with 420 citations (h-index 7); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingClinical trials
- Three Year Outcomes of Combined Hydrus Microstent With iTrack Canaloplasty
Sponsor: University of Utah
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
6 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
78.5%Prostaglandin Analog36.9%Latanoprost83%Lumigan17%Part D≥110 patientsCarbonic Anhydrase Inhibitor26.8%Dorzolamide-Timolol81%Dorzolamide Hcl9%Acetazolamide Er6%Brinzolamide4%Part D<11 patients+ 3 more classes in this area
Musculoskeletal
13.9%Cyclooxygenase Inhibitor13.9%Ketorolac Tromethamine100%Part D≥101 patientsCardiovascular
4.6%Beta blocker4.6%Timolol Maleate100%Part D≥23 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The Use of Ologen Collagen Matrix in Combination with XEN45 Microstent for the Treatment of Glaucoma: A Retrospective Chart Review
Journal of Clinical & Translational Ophthalmology
2025 - The relationship between intraocular pressure and glaucoma: An evolving concept
Progress in Retinal and Eye Research
2024 - A Health-Related Quality of Life Measure for Patients Who Undergo Minimally Invasive Glaucoma Surgery
American Journal of Ophthalmology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Colman, MD
University of Utah
Michael Varner, MD
University of Utah
James Fang
University of Utah
Wallace Akerley, MD
University of Utah
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”